How Analysts Feel About Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)?

May 8, 2018 - By Vivian Currie

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Logo

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 4 analyst reports since November 15, 2017 according to SRatingsIntel. The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has “Buy” rating given on Monday, December 4 by Raymond James. On Friday, March 23 the stock rating was maintained by B. Riley & Co with “Buy”. Below is a list of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) latest ratings and price target changes.

23/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7 Initiates Coverage On
23/03/2018 Broker: B. Riley & Co Old Rating: Buy New Rating: Buy Old Target: $7.5 New Target: $6.25 Maintain
04/12/2017 Broker: Raymond James Rating: Buy New Target: $7.0 Maintain
15/11/2017 Broker: FBR Capital Rating: Buy New Target: $9.5

The stock increased 2.01% or $0.075 during the last trading session, reaching $3.8. About 332,253 shares traded. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 20.00% since May 8, 2017 and is downtrending. It has underperformed by 31.55% the S&P500.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $126.88 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

More recent Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) news were published by: Seekingalpha.com which released: “Adamis Keeps Us Waiting: April Update” on April 28, 2018. Also Prnewswire.com published the news titled: “Pre-Market Technical Scan on Drug Delivery Equities — Adamis Pharma, Alkermes, PetMed Express, and Valeant …” on May 04, 2018. Nasdaq.com‘s news article titled: “Recent Analysis Shows J.Jill, BankUnited, Toronto Dominion Bank, Adamis Pharmaceuticals, BioDelivery Sciences …” with publication date: April 19, 2018 was also an interesting one.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: